Home » Stocks » SBTX

Silverback Therapeutics, Inc. (SBTX)

Stock Price: $48.32 USD -1.46 (-2.93%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 1.68B
Revenue (ttm) n/a
Net Income (ttm) -26.83M
Shares Out 33.07M
EPS (ttm) -0.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $48.32
Previous Close $49.78
Change ($) -1.46
Change (%) -2.93%
Day's Open 50.00
Day's Range 48.20 - 54.41
Day's Volume 97,790
52-Week Range 25.00 - 54.41

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 2 weeks ago

Silverback Therapeutics Inc (NASDAQ: SBTX) recently raised $277.7 million by selling 13.225 million shares in an initial public offering that were priced at $21 each. The Silverback Analyst: S...

Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: CAR, ARDX, CNNE, MPLN, SEER
Business Wire - 1 month ago

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to de...

Seeking Alpha - 1 month ago

The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and A...

Other stocks mentioned: FTCVU, KNTE, LOKBU, POWW, SEER, SGAMU, YQ
Investors Business Daily - 1 month ago

The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.

Other stocks mentioned: SEER
GeekWire - 1 month ago

Silverback Therapeutics will raise $241.

Business Wire - 1 month ago

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemica...

Market Watch - 1 month ago

Silverback Therapeutics Inc. upsized its initial public offering to 10.00 million shares, and the expected pricing of the offering increased to between $19 and $20 a share. The Seattle-based b...

TheStreet - 2 months ago

Seattle, Washington-based Silverback was founded to create what it calls its ImmunoTAC platform to develop 'systematically delivered, tissue targeted therapeutics' by pairing 'proprietary link...

Endpoints News - 2 months ago

The signs were there: A couple of months ago, Silverback Therapeutics quickly pulled in $163 million in two back-to-back rounds for what CEO Laura Shawver called “an important growth phase.” A...

Fierce Biotech - 2 months ago

Silverback Therapeutics is on a roll. After banking more than $160 million in venture capital this year, the immuno-oncology biotech filed on Tuesday to raise up to $100 million in its Wall St...

GeekWire - 2 months ago

Silverback Therapeutics filed for an initial public offering on Tuesday, seeking additional capital as it develops targeted therapeutics for cancer, viral infections and other diseases, led by...

NASDAQ - 2 months ago

Silverback Therapeutics, a Phase 1 biotech developing therapeutics for solid tumors and other diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

SEC - 2 months ago

Silverback Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

About SBTX

Silverback Therapeutics, a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-... [Read more...]

Industry
Biotechnology
IPO Date
Dec 4, 2020
CEO
Laura Shawver
Employees
52
Stock Exchange
NASDAQ
Ticker Symbol
SBTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SBTX stock is "Buy." The 12-month stock price forecast is 46.25, which is a decrease of -4.28% from the latest price.

Price Target
$46.25
(-4.28% downside)
Analyst Consensus: Buy